Haleon PLC Announces Total Voting Rights and Capital Update

The latest announcement is out from Haleon PLC Sponsored ADR ( (HLN) ).

On September 1, 2025, Haleon PLC reported that as of August 31, 2025, the total number of shares issued was 8,959,221,411, with 3,880,205 held as treasury shares. Consequently, the number of ordinary shares with voting rights stands at 8,955,341,206. This figure is crucial for shareholders and others with notification obligations to determine their interest in the company under the FCA’s Disclosure Guidance and Transparency Rules.

The most recent analyst rating on (HLN) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

Haleon PLC’s overall stock score reflects a strong financial position and operational improvements, particularly in international markets. However, challenges in North America and stagnant revenue growth weigh on the score. Technical indicators and valuation suggest moderate potential for growth, with no significant corporate events impacting the assessment.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon PLC is a global leader in consumer health, focusing on delivering better everyday health with a human touch. The company offers a diverse range of products across six major categories, including Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Its portfolio features well-known brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 11,809,654

Technical Sentiment Signal: Buy

Current Market Cap: $44B

See more insights into HLN stock on TipRanks’ Stock Analysis page.